News 09.11.2017 Neurimmune, a global leader in the discovery and development of human-derived monoclonal antibodies, today announced that it has entered into a collaboration with Ono Pharmaceutical Co., Ltd. focused on the development of human antibodies against a novel therapeutic target for neurodegenerative diseases. Under the terms of the collaboration agreement Neurimmune...
Internal events
Event date: 22.01.2018
We are pleased to invite you to the first Life Science Zurich Impact conference on translational medicine, which is taking place on January 22, 2018 at the Technopark Zurich, Switzerland.
This one-day multi-track meeting is organised by the Life Science Zurich Business Network, the University of Zurich, the ETH, the Canton...
News 24.10.2017 Neurimmune announced today that it has raised $150 million to fund its growth strategy. The financing will accelerate the development of Neurimmune's human antibody pipeline through clinical proof of concept. Neurimmune receives a one-time $150 million payment from its collaboration partner Biogen in exchange for a 15% reduction in the previously...
External events
Event date: 27.09.2017
You plan to protect and use your invention without getting a patent. You want to protect and sell your product without registering your brand or design. What options are available? How are these implemented? It is important to protect intellectual property. This is usually done through patents, trademarks, designs and...
News 30.08.2017 Biogen (NASDAQ: BIIB) announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment for early Alzheimer’s disease. The updated analyses include data from the placebo-controlled period and LTE for patients treated with aducanumab up to 24...